Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.34 |
| ▸ | ITGAL | P20701 | 1/20 | 0.34 |
| ▸ | EP300 | Q09472 | 3/20 | 0.33 |
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | CTSG | P08311 | 1/20 | 0.33 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.33 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13581345 | 1.00 | LMNA (0.42) | LMNAITGB2ICAM1ITGALEP300 | |
| SCHEMBL13581336 | 0.85 | LMNA (0.38) | LMNAELANECTSGPRTN3CAPN1 | |
| SCHEMBL13581348 | 0.72 | TRPA1 (0.30) | CES2CES1 | |
| Paramethadione SCHEMBL317346 | 0.70 | LMNA (0.56) | LMNAELANECTSGPRTN3 | |
| SCHEMBL1363134 | 0.69 | LMNA (0.54) | LMNA | |
| SCHEMBL13581326 | 0.68 | HCAR2 (0.40) | LMNAELANECTSGPRTN3 | |
| SCHEMBL9203921 | 0.64 | PDE3B (0.48) | LMNAELANECTSGPRTN3 | |
| Trimethadione SCHEMBL28882 | 0.61 | LMNA (1.00) | LMNAELANECTSGPRTN3 | |
| SCHEMBL9027679 | 0.60 | MEN1 (0.51) | — | |
| SCHEMBL131361 | 0.59 | ALDH1A1 (0.67) | CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625933-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080119531-A1 | PPAR gamma agonists or partial agonists; type II diabetes, including hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity; compounds have a thiazolidinedione or an oxazolidinedione substituent | MERCK SHARP & DOHME CORP. | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119531-A1 | PPAR gamma agonists or partial agonists; type II diabetes, including hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity; compounds have a thiazolidinedione or an oxazolidinedione substituent | PPARD, PPARG, PPARA | LMNA 2853/4885ITGB2 2911/4885ICAM1 4176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.